Praxis Precision Medicines, Inc. · Healthcare · Biotechnology
Scores & Status Key
AI Summary Scores: Intraday / Swing / Long scores are synthesized from multi-factor analysis for each timeframe. They summarize current conditions discussed in the report and do not constitute trading recommendations.
Intraday Trend Score: A 0–100 composite from the Trend Explorer™ analytics engine used for ranking and comparison. It describes current conditions and is not a forecast.
Trend Status: A rules-based label (Bullish / Mixed / Bearish) derived from signal confluence (trend structure, momentum, and positioning). It indicates alignment, not expected return.
Last
$333.69
+$13.30 (+4.15%) 9:59 AM ET
Prev closePrevC$320.39
OpenOpen$328.96
Day highHigh$337.19
Day lowLow$327.69
VolumeVol37,381
Avg volAvgVol419,524
On chart
Interval
Intervals apply to 1D & 5D.
Intervals apply to 1D & 5D.
Scale: Linear
Overlays
Panels
Style
Scale: Linear
Presets
Tools
Tickers only (no ^ indexes). Add up to 5.
Mkt cap
$9.47B
P/E ratio
-24.77
EPS
-13.47
Sector
Healthcare
AI report sections
MIXED
PRAX
Praxis Precision Medicines, Inc.
No AI report section text found yet for this symbol.
Praxis Precision Medicines (NASDAQ: PRAX) shares surged 7.15% on Tuesday following FDA acceptance of its New Drug Application for ulixacaltamide, a treatment for essential tremor, with an FDA decision target date of January 29, 2027. The company also reported positive Phase 3 trial results and significant seizure reduction data from its elsunersen program. The stock is trading near its 52-week high with strong technical momentum and a Buy rating from analysts with a $588.60 average price target.
FDA acceptance of NDA with January 2027 decision date, positive Phase 3 trial data showing statistically significant improvements, significant seizure reduction results (77% placebo-adjusted reduction), stock trading near 52-week highs with strong 12-month performance (+1038.45%), analyst Buy rating with $588.60 price target, and neutral RSI suggesting room for further upside movement.
PositiveGlobeNewswire Inc.• Na
Praxis Precision Medicines Announces Positive Results from the EMBRAVE Part A Trial of Elsunersen in Patients with SCN2A Early-Onset Developmental and Epileptic Encephalopathy
Praxis Precision Medicines announced positive Phase 1/2 trial results for elsunersen (PRAX-222), an antisense oligonucleotide treatment for SCN2A developmental and epileptic encephalopathy. The drug demonstrated a 77% placebo-adjusted seizure reduction, with 71% of treated patients achieving >50% seizure reduction. All elsunersen-treated patients showed improvements in sleep, motor function, and attention, with no serious adverse events reported.
PRAXIONSelsunersenSCN2Adevelopmental and epileptic encephalopathyantisense oligonucleotideseizure reductionclinical trial
Sentiment note
The company announced strong Phase 1/2 trial results showing 77% placebo-adjusted seizure reduction with a favorable safety profile and no serious adverse events. The drug demonstrated disease-modifying improvements and sustained benefits, supporting advancement toward pivotal Phase 3 trials (EMBRAVE3).
PositiveThe Motley Fool• Jonathan Ponciano
This Biotech Stock Up 700% Is Still a Top Holding Despite a $9.3 Million Sale Last Quarter
Cormorant Asset Management sold 50,000 shares of Praxis Precision Medicines (PRAX) in Q4 2025 for $9.31 million, but the position still increased by $227 million in value due to stock appreciation. PRAX remains Cormorant's largest holding at $280 million. The biotech stock has surged 700% over the past year and is advancing multiple late-stage therapies for neurological disorders with strong cash reserves of $926 million.
Stock up 700% in one year, largest holding in fund portfolio, advancing multiple late-stage therapies with FDA submissions, strong balance sheet with $926M in cash and $621M recent funding, positioned for transition to commercial drug maker
PositiveThe Motley Fool• Jonathan Ponciano
Praxis Stock Has Surged 700% in a Year, and This Fund Is Betting $266 Million on Its Pipeline
Deerfield Management Company increased its stake in Praxis Precision Medicines by 62,500 shares, bringing its total position to $266.25 million. PRAX stock has surged 685% over the past year, significantly outperforming the S&P 500. The biotech company recently submitted FDA applications for two drug candidates and has four leading programs that could represent over $20 billion in potential revenue if successfully commercialized. With $926 million in cash and a recent $621 million offering, Praxis is well-positioned financially through 2028.
PRAXbiotechclinical-stageFDA approvalcentral nervous system disordersdrug pipelineinstitutional investmentstock surge
Sentiment note
Strong stock performance (685% gain over one year), major institutional investment from Deerfield Management, recent FDA drug application submissions, substantial cash position ($926M+), and significant revenue potential ($20B+) from pipeline candidates support positive outlook despite clinical-stage risks.
PositiveThe Motley Fool• Jonathan Ponciano
Biotech Stock Up 685% Draws $80.5 Million Investment Amid Dual FDA Filings
Praxis Precision Medicines (PRAX) has surged 685% over the past year, attracting an $80.5 million investment from Driehaus Capital Management. The clinical-stage biotech company recently submitted two FDA applications for therapies targeting essential tremor and rare developmental epilepsies. With $926 million in cash and potential revenue exceeding $20 billion if approved, the company is positioned for significant growth, though regulatory approval remains a key risk.
PRAXTSMGHbiotechFDA filingsclinical-stage therapiescentral nervous system disordersstock surge
Sentiment note
Strong 685% stock appreciation over the past year, significant institutional investment of $80.5 million, dual FDA drug applications submitted, substantial cash position ($926 million), and CEO guidance indicating potential revenue exceeding $20 billion if programs are successfully commercialized. These factors indicate strong investor confidence and significant growth potential.
PositiveThe Motley Fool• Jonathan Ponciano
Praxis Stock Surges 320% as One Biotech Investor's Buy Pushes Stake to Nearly $600 Million
Perceptive Advisors increased its stake in Praxis Precision Medicines by 431,432 shares (worth ~$80.34 million) in Q4 2025, bringing its total position to $588.30 million and making it the fund's largest holding at 10.8% of AUM. The biotech company's stock has surged 320% over the past year as it advances toward commercialization with two FDA NDAs submitted and a strong cash position of $1.547 billion.
Stock has surged 320% year-over-year, major institutional investor (Perceptive Advisors) significantly increased stake to $588.30 million, company has two NDAs submitted to FDA, strong cash position of $1.547 billion extending runway to 2028, and multiple Phase 3 readouts expected in 2026 representing near-term catalysts.
NeutralThe Motley Fool• Lawrence Rothman, Cfa
Soleus Adds a Significant Number of Celcuity Shares
Soleus Capital Management increased its stake in Celcuity by 629,398 shares, bringing its total holdings to over 1.8 million shares valued at $180.36 million. This purchase elevated Celcuity to Soleus's third-largest holding, representing 6.7% of the fund's AUM. The move signals bullish confidence in the clinical-stage biotech company, which has seen its stock surge 745% over the past year.
CELCKRYSNVCRPRAXSoleus Capital ManagementCelcuitybiotech investmentcancer therapeutics
Sentiment note
Listed as fifth-largest holding in Soleus's portfolio ($107.0 million, 3.9% of AUM) but no specific transaction or news mentioned in the article.
PositiveGlobeNewswire Inc.• Na
Praxis Precision Medicines Further Positioned for Next-Phase Growth with Key Board and Executive Appointments
Praxis Precision Medicines announced strategic leadership changes to support its transition into late-stage development and commercial execution. The company appointed Jeffrey B. Kindler (former Pfizer CEO) and Stuart Arbuckle (former Vertex COO) to its board of directors, and promoted Megan Sniecinski to Chief Operating Officer and Dr. Steven Petrou to President of Research & Development. These moves align with the company's focus on commercial launch planning, late-stage development, and strategic value optimization for its CNS disorder therapies.
The company is making strategic leadership appointments with highly experienced executives from major pharmaceutical companies (Pfizer, Vertex, Amgen, GSK), signaling confidence in advancing toward commercialization. The promotions of internal executives demonstrate organizational maturity and readiness for the next growth phase. The timing coincides with a $575 million public offering, indicating strong market positioning and investor confidence in the company's pipeline and strategic direction.
PositiveGlobeNewswire Inc.• Na
Praxis Precision Medicines, Inc. Announces Pricing of $575 Million Public Offering
Praxis Precision Medicines priced an underwritten public offering of 2.212 million shares at $260 per share, generating approximately $575 million in gross proceeds. The offering is expected to close on January 8, 2026, with underwriters granted a 30-day option to purchase an additional 331,800 shares. The company is a clinical-stage biopharmaceutical firm focused on CNS disorder therapies.
The company successfully priced a substantial $575 million public offering at $260 per share, demonstrating strong investor confidence and market demand. This significant capital raise provides substantial funding for the company's clinical development programs, particularly for its CNS disorder therapies.
NeutralBenzinga• Globe Newswire
Praxis Precision Medicines, Inc. Announces Proposed Public Offering
Praxis Precision Medicines (NASDAQ: PRAX), a clinical-stage biopharmaceutical company focused on CNS disorders, announced a proposed public offering of common stock and pre-funded warrants. The offering is being managed by Piper Sandler, TD Cowen, Guggenheim Securities, and Truist Securities as joint book-running managers, with completion subject to market conditions.
The announcement of a public offering is a standard corporate action. While it provides capital for the company's operations, the stock price declined 4.12% on the announcement date, suggesting investor caution. The offering itself is neither inherently positive nor negative, as it depends on market conditions and how proceeds are utilized.
PositiveThe Motley Fool• Joe Tenebruso
Why Praxis Precision Medicines Stock Popped Today
Praxis Precision Medicines stock surged 13.25% after receiving FDA Breakthrough Therapy Designation for ulixacaltamide, an experimental treatment for essential tremor. The designation, based on positive phase 3 study results, will accelerate the drug's development and regulatory review, with a New Drug Application planned for early 2026. Essential tremor affects approximately 7 million people in the U.S. with limited effective treatment options.
Company received FDA Breakthrough Therapy Designation for its experimental tremor treatment based on positive phase 3 results, accelerating development timeline and addressing a large unmet medical need affecting 7 million U.S. patients. Stock price increased 13.25% on the announcement.
PositiveGlobeNewswire Inc.• Na
Praxis Precision Medicines Announces the FDA Has Granted Breakthrough Therapy Designation for Ulixacaltamide HCl in Essential Tremor
Praxis Precision Medicines received FDA Breakthrough Therapy Designation for ulixacaltamide, a T-type calcium channel inhibitor for essential tremor treatment, based on positive Phase 3 Essential3 program results. The company plans to submit a New Drug Application (NDA) in early 2026 following a successful pre-NDA meeting with the FDA.
The company received FDA Breakthrough Therapy Designation, which accelerates development and regulatory review. Positive Phase 3 trial results and successful pre-NDA alignment with FDA support faster advancement toward commercialization. The designation addresses a significant unmet medical need in a large patient population (7 million in the US), representing substantial commercial opportunity.
News and sentiment labels describe article tone and are provided for research purposes only. They are not trading recommendations or forecasts.
Trade Ranks App
Trade Ranks, LLC is not a registered investment adviser or broker-dealer. All rankings and AI reports are for informational and educational purposes only and are not personalized advice. Investing involves risk. Policy Portal